Detailed information for compound 349155

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 225.675 | Formula: C10H12ClN3O
  • H donors: 2 H acceptors: 2 LogP: 1.27 Rotable bonds: 2
    Rule of 5 violations (Lipinski): 1
  • SMILES: C[C@@H](Cn1ncc2c1c(Cl)c(O)cc2)N
  • InChi: 1S/C10H12ClN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
  • InChiKey: VCXUEWRCJZWCJB-LURJTMIESA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Serotonin 2a (5-HT2a) receptor Starlite/ChEMBL References
Rattus norvegicus Serotonin 2b (5-HT2b) receptor Starlite/ChEMBL References
Homo sapiens 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled Starlite/ChEMBL References
Rattus norvegicus Serotonin 2c (5-HT2c) receptor Starlite/ChEMBL References
Homo sapiens 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled Starlite/ChEMBL References
Homo sapiens 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus granulosus hypothetical protein Get druggable targets OG5_144688 All targets in OG5_144688
Echinococcus multilocularis conserved hypothetical protein Get druggable targets OG5_144688 All targets in OG5_144688
Brugia malayi Serotonin receptor Get druggable targets OG5_135430 All targets in OG5_135430

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma japonicum ko:K04209 neuropeptide Y receptor, invertebrate, putative Serotonin 2a (5-HT2a) receptor   471 aa 405 aa 25.4 %
Echinococcus granulosus g protein coupled receptor Serotonin 2a (5-HT2a) receptor   471 aa 416 aa 19.2 %
Echinococcus multilocularis g protein coupled receptor Serotonin 2a (5-HT2a) receptor   471 aa 462 aa 21.2 %
Echinococcus granulosus g protein coupled receptor Serotonin 2a (5-HT2a) receptor   471 aa 408 aa 21.8 %
Loa Loa (eye worm) hypothetical protein Serotonin 2c (5-HT2c) receptor   460 aa 417 aa 21.3 %
Echinococcus multilocularis neuropeptides capa receptor Serotonin 2c (5-HT2c) receptor   460 aa 408 aa 20.8 %
Schistosoma mansoni amine GPCR Serotonin 2b (5-HT2b) receptor   479 aa 416 aa 30.8 %
Schistosoma japonicum ko:K04136 adrenergic receptor, alpha 1b, putative Serotonin 2a (5-HT2a) receptor   471 aa 422 aa 27.5 %
Schistosoma japonicum IPR000276,Rhodopsin-like GPCR superfamily,domain-containing Serotonin 2b (5-HT2b) receptor   479 aa 418 aa 21.8 %
Onchocerca volvulus Ubiquinol-cytochrome-c reductase complex assembly factor 1 homolog Serotonin 2a (5-HT2a) receptor   471 aa 435 aa 23.0 %
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Serotonin 2c (5-HT2c) receptor   460 aa 405 aa 31.1 %
Echinococcus multilocularis g protein coupled receptor Serotonin 2a (5-HT2a) receptor   471 aa 417 aa 20.6 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Schistosoma mansoni dihydrofolate reductase 0.618 1 1
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.618 1 1
Echinococcus granulosus dihydrofolate reductase 0.618 1 1
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.3046 0.4438 0.5
Loa Loa (eye worm) dihydrofolate reductase 0.618 1 1
Onchocerca volvulus 0.0546 0 0.5
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.3046 0.4438 0.5
Brugia malayi Dihydrofolate reductase 0.618 1 1
Echinococcus granulosus hypothetical protein 0.1684 0.202 0.202
Brugia malayi Serotonin receptor 0.1128 0.1034 0.1034
Leishmania major dihydrofolate reductase-thymidylate synthase 0.3046 0.4438 0.5
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.618 1 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.3046 0.4438 0.5
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.3046 0.4438 0.5
Echinococcus multilocularis conserved hypothetical protein 0.1667 0.1989 0.1989
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.618 1 1
Echinococcus multilocularis dihydrofolate reductase 0.618 1 1
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.3046 0.4438 0.5
Chlamydia trachomatis dihydrofolate reductase 0.618 1 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 18.4 % Lowering of intraocular pressure in lasered cynomolgus monkey after 1 hr at 300 ug ChEMBL. 16392816
Activity (functional) = 18.4 % Lowering of intraocular pressure in lasered cynomolgus monkey after 1 hr at 300 ug ChEMBL. 16392816
Activity (functional) = 30.8 % Lowering of intraocular pressure in lasered cynomolgus monkey after 3 hrs at 300 ug ChEMBL. 16392816
Activity (functional) = 30.8 % Lowering of intraocular pressure in lasered cynomolgus monkey after 3 hrs at 300 ug ChEMBL. 16392816
Activity (functional) = 32.7 % Lowering of intraocular pressure in lasered cynomolgus monkey after 6 hrs at 300 ug ChEMBL. 16392816
Activity (functional) = 32.7 % Lowering of intraocular pressure in lasered cynomolgus monkey after 6 hrs at 300 ug ChEMBL. 16392816
EC50 (functional) = 4.9 nM Activity against recombinant rat 5HT2C mediated intracellular calcium mobilization by FLIPR in SR3T3 cells ChEMBL. 16392816
EC50 (functional) = 4.9 nM Activity against recombinant rat 5HT2C mediated intracellular calcium mobilization by FLIPR in SR3T3 cells ChEMBL. 16392816
EC50 (functional) = 5.9 nM Activity against 5HT2B receptor in longitudinal stomach fundus strips in wistar rats ChEMBL. 16392816
EC50 (functional) = 5.9 nM Activity against 5HT2B receptor in longitudinal stomach fundus strips in wistar rats ChEMBL. 16392816
EC50 (functional) = 59.7 nM Activity against 5HT2A mediated intracellular calcium mobilization by FLIPR in rat vascular smooth muscle cells ChEMBL. 16392816
EC50 (functional) = 59.7 nM Activity against 5HT2A mediated intracellular calcium mobilization by FLIPR in rat vascular smooth muscle cells ChEMBL. 16392816
ED5 (functional) = 0.56 mg kg-1 Head twitch response in SD mice, sc ChEMBL. 16392816
ED5 (functional) = 0.56 mg kg-1 Head twitch response in SD mice, sc ChEMBL. 16392816
Emax (functional) = 87 % Activity against 5HT2A mediated intracellular calcium mobilization by FLIPR in rat vascular smooth muscle cells ChEMBL. 16392816
Emax (functional) = 87 % Activity against 5HT2A mediated intracellular calcium mobilization by FLIPR in rat vascular smooth muscle cells ChEMBL. 16392816
Emax (functional) = 104 % Activity against recombinant rat 5HT2C mediated intracellular calcium mobilization by FLIPR in SR3T3 cells ChEMBL. 16392816
Emax (functional) = 104 % Activity against recombinant rat 5HT2C mediated intracellular calcium mobilization by FLIPR in SR3T3 cells ChEMBL. 16392816
IC50 (binding) = 0.54 nM Inhibition of [125I]DOI binding to 5HT2A receptor in rat cerebral cortex ChEMBL. 16392816
IC50 (binding) = 0.54 nM Inhibition of [125I]DOI binding to 5HT2A receptor in rat cerebral cortex ChEMBL. 16392816
Ki (binding) = 1.2 nM Displacement of [125I]DOI from cloned human 5HT2C receptor expressed in CHO cells ChEMBL. 16392816
Ki (binding) = 1.2 nM Displacement of [125I]DOI from cloned human 5HT2C receptor expressed in CHO cells ChEMBL. 16392816
Ki (binding) = 3.8 nM Displacement of [125I]DOI from cloned human 5HT2B receptor expressed in CHO cells ChEMBL. 16392816
Ki (binding) = 3.8 nM Displacement of [125I]DOI from cloned human 5HT2B receptor expressed in CHO cells ChEMBL. 16392816
Ki (binding) = 12 nM Displacement of [125I]DOI from cloned human 5HT2A receptor expressed in CHO cells ChEMBL. 16392816
Ki (binding) = 12 nM Displacement of [125I]DOI from cloned human 5HT2A receptor expressed in CHO cells ChEMBL. 16392816
Log D = 1.09 Distribution coefficient at pH 7.4 ChEMBL. 16392816
Papp (ADMET) = 13.6 nM/s Passive diffusion permeability from apical to basolateral side of the MDCK cell transfected with human MDR1 in presence of cyclosporin A ChEMBL. 16392816
Papp (ADMET) = 16.5 nM/s Permeability from apical to basolateral side of the MDCK cell transfected with human MDR1 ChEMBL. 16392816
Papp (ADMET) = 32.5 nM/s Passive diffusion permeability from basolateral to apical side of the MDCK cell transfected with human MDR1 in presence of cyclosporin A ChEMBL. 16392816
Papp (ADMET) = 49.4 nM/s Permeability from basolateral to apical side of the MDCK cell transfected with human MDR1 ChEMBL. 16392816
Ratio (ADMET) = 2.4 Ratio of passive diffusion permeability from basolateral to apical over apical to basolateral side of the MDCK cell transfected with MDR1 in presence of cyclosporin A ChEMBL. 16392816
Ratio (ADMET) = 3 Ratio of permeability from basolateral to apical over apical to basolateral side of the MDCK cell transfected with human MDR1 ChEMBL. 16392816
T1/2 (ADMET) = 4 yr Half life in phosphate buffer at pH 7.4 in 25 degC ChEMBL. 16392816

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.